View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2017	Nov. 08, 2017
Document Information [Line Items]
Entity Registrant Name	WINDTREE THERAPEUTICS INC /DE/
Entity Central Index Key	0000946486
Trading Symbol	wint
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		63,213,973
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 1,752	$ 5,588
Prepaid interest, current portion	1,094	1,094
Prepaid expenses and other current assets	248	512
Total current assets	3,094	7,194
Property and equipment, net	930	1,054
Restricted cash	225	225
Prepaid interest, non-current portion	408	1,226
Total assets	4,657	9,699
Current Liabilities:
Accounts payable	3,770	1,813
Collaboration payable	4,183	3,967
Accrued expenses	5,365	7,611
Deferred revenue	1,070
Loan payable	2,600
Long-term debt, current portion	12,500
Total current liabilities	29,488	13,391
Long-term debt, non-current portion	12,500	25,000
Other liabilities	117	138
Total liabilities	42,105	38,529
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 3,203 and 0 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively
Common stock, $0.001 par value; 120,000,000 and 60,000,000 shares authorized at September 30, 2017 and December 31, 2016, respectively; 15,543,738 and 8,725,069 shares issued at September 30, 2017 and December 31, 2016, respectively; 15,542,246 and 8,723,577 shares outstanding at September 30, 2017 and December 31, 2016, respectively	16	9
Additional paid-in capital	605,177	592,883
Accumulated deficit	(639,587)	(618,668)
Treasury stock (at cost); 1,492 shares	(3,054)	(3,054)
Total stockholders' equity	(37,448)	(28,830)
Total liabilities & stockholders' equity	$ 4,657	$ 9,699

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	3,203	0
Preferred stock, shares outstanding (in shares)	3,203	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	120,000,000	60,000,000
Common stock, shares issued (in shares)	15,543,738	8,725,069
Common stock, shares outstanding (in shares)	15,542,246	8,723,577
Treasury stock, shares (in shares)	1,492	1,492

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues:
Grant revenue	$ 17	$ 961	$ 1,383	$ 1,142
Expenses:
Research and development	3,062	7,081	14,958	25,757
General and administrative	1,749	1,613	5,475	7,053
Total operating expense	4,811	8,694	20,433	32,810
Operating loss	(4,794)	(7,733)	(19,050)	(31,668)
Change in fair value of common stock warrant liability				223
Other income / (expense):
Interest income	3	3	9	15
Interest expense	(652)	(648)	(1,878)	(1,907)
Other income		15		449
Other income / (expense), net	(649)	(630)	(1,869)	(1,443)
Net loss	(5,443)	(8,363)	(20,919)	(32,888)
Deemed dividend on Series A preferred stock	(1,915)		(6,051)
Net loss attributable to common shareholders	$ (7,358)	$ (8,363)	$ (26,970)	$ (32,888)
Net loss per common share
Basic and diluted (in dollars per share)	$ (0.69)	$ (1)	$ (2.76)	$ (3.98)
Weighted average number of common shares outstanding
Basic and diluted (in shares)	10,647	8,355	9,766	8,262

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (20,919)	$ (32,888)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	147	199
Stock-based compensation and 401(k) plan employer match	839	1,301
Fair value adjustment of common stock warrants		(223)
Amortization of prepaid interest	818	1,435
Gain/(loss) on sale or disposal of equipment		(16)
Changes in:
Prepaid expenses and other current assets	264	152
Accounts payable	3,155	1,702
Collaboration payable	216	601
Accrued expenses	(1,827)	969
Deferred revenue	1,070
Other liabilities		124
Net cash used in operating activities	(16,237)	(26,644)
Cash flows from investing activities:
Purchase of property and equipment	(24)	(193)
Proceeds from sale of property and equipment		27
Net cash used in investing activities	(24)	(166)
Cash flows from financing activities:
Proceeds from Private Placement issuance of securities, net of expenses	8,789
Proceeds from ATM Program, net of expenses	1,036	471
Proceeds from loan payable	2,600
Net cash provided by financing activities	12,425	471
Net increase/(decrease) in cash and cash equivalents	(3,836)	(26,339)
Cash, cash equivalents and restricted cash - beginning of year	5,813	38,947
Cash, cash equivalents and restricted cash - end of year	1,977	12,608
Supplementary disclosure of cash flows information:
Interest paid	$ 514	$ 61

Note 1 - The Company and Description of Business

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note

–

The Company and Description of Business

Windtree Therapeutics, Inc. (referred to as “we,” “us,” or the “Company”) is a biotechnology company focused on developing novel KL

surfactant therapies for respiratory diseases and other potential applications. Surfactants are produced naturally in the lung and are essential for normal respiratory function and survival. Our proprietary technology platform includes a synthetic, peptide-containing surfactant (KL

surfactant) that is structurally similar to endogenous pulmonary surfactant, and novel drug delivery technologies being developed to enable noninvasive administration of aerosolized KL

surfactant. We believe that our proprietary technology platform

may

make it possible to develop a pipeline of surfactant products to address a variety of respiratory diseases for which there are few or

approved therapies.

Our lead development program is AEROSURF

(lucinactant for inhalation), an investigational combination drug/device product that combines our KL

surfactant with our novel aerosol delivery system (ADS). We are developing AEROSURF to improve the management of respiratory distress syndrome (RDS) in premature infants. RDS is a serious respiratory condition caused by a deficiency of natural lung surfactant in lungs of premature infants, and the most prevalent respiratory disease in the neonatal intensive care unit. By enabling administration of aerosolized KL

surfactant, AEROSURF

may

reduce or eliminate the need for invasive endotracheal intubation and mechanical ventilation, which currently are required to administer life-saving surfactant therapy, but which are associated with serious respiratory conditions and other complications. To avoid the risks of surfactant administration, many neonatologists initially delay surfactant therapy and treat premature infants with noninvasive respiratory support (such as nasal continuous positive airway pressure (nCPAP)). We believe that AEROSURF, if approved, has the potential to address a serious unmet medical need by enabling earlier KL

surfactant therapy for infants receiving nCPAP alone, reducing the number of premature infants who are subjected to invasive surfactant administration, and potentially providing transformative clinical and pharmacoeconomic benefits.

June 2017,

we announced that w

e had completed an AEROSURF phase

clinical trial that was designed to evaluate aerosolized KL

surfactant administered to premature infants

week gestational age receiving nCPAP, in

two

dose groups (

and

minutes) with up to

two

potential repeat doses, compared to infants receiving nCPAP alone. This trial was conducted in approximately

clinical sites in the U.S., Canada, the European Union and Latin America. Based on the planned top-line results, data show that AEROSURF did

not

meet the primary endpoint of a reduction in nCPAP failure at

hours, which we believe was due in large part to an unexpected rate of treatment interruptions. Such interruptions occurred in about

24%

of active enrollments, predominantly in the

minute dose group, and we believe were primarily related to specific lots of disposable cartridge filters with a higher tendency to clog. After excluding the patients whose dose was interrupted in the

minute dose group, the data show an nCPAP failure rate of

32%

compared to

44%

in the control group which is a

12%

absolute reduction or a

27%

relative reduction in nCPAP failure compared to control. These data suggest a meaningful treatment effect in line with our targeted outcome.

We are currently focused on our project with Battelle Memorial Institute

(Battelle) to complete development of our next generation aerosol delivery device (NextGen ADS), which is intended to replace the prototype device used in our phase

clinical trials. The NextGen ADS combines the same aerosolization technology used during the phase

clinical program, but with improved ergonomics, interface, controls, and dose monitoring in a modular design. Design verification and validation are underway. Within this process, we are assessing whether the design of the NextGen ADS successfully mitigates the risk of clogging and related treatment interruptions that occurred during the Phase

clinical trial. To verify the design and confirm the performance of the NextGen ADS,

including with respect to device-related treatment interruptions experienced with the phase

prototype ADS, w

e are planning to conduct a device bridging and confirmation clinical study

(i) to gain experience with the next generation ADS (NextGen ADS), (ii) to confirm whether our development objectives have been met and (iii) to generate additional higher dose treatment data to augment the higher dose data obtained in the phase

clinical trial, which was adversely affected by treatment interruptions.

We currently are assessing the potential design and requirements for this trial.

In addition, in

June 2017,

we and a Hong Kong company, Lee

’s Pharmaceutical (HK), Ltd. (Lee’s (HK)), entered into an exclusive license and collaboration agreement (License Agreement) for the development and commercialization of KL

surfactant products in China, Hong Kong and other select Asian markets, with a future option to potentially add Japan. The agreement includes AEROSURF as well as the non-aerosol products, SURFAXIN

(approved in the U.S. in

2012

) and SURFAXIN LS™ (an improved lyophilized formulation of SURFAXIN). We also granted Lee’s (HK) an exclusive license to manufacture KL

surfactant in China for use in non-aerosol surfactant products in the licensed territory and a future option to manufacture the device in the licensed territory. In connection with the

August 2017

Loan Agreement with Lee's (HK) (

see,

“– Note

– Loan Payable”), we amended the License Agreement to expand certain of Lee’s (HK) rights, including by immediately adding Japan to the licensed territory, accelerating the right to manufacture the ADS in and for the licensed territory, reducing or eliminating certain of the milestone and royalty payments and adding an affiliate of Lee’s (HK) as a party to the License Agreement. We are presently engaged in a technology transfer of our KL

surfactant manufacturing process to Lee’s (HK).

Note 2 - Liquidity Risks and Management's Plans

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Liquidity Disclosures [Text Block]

Note

–

Liquidity Risks and Management

’s Plans

As of

September 30, 2017,

we had cash and cash equivalents of

$1.8

million, current liabilities of

$29.5

million (including

$12.5

million of long-term debt, current portion) and

$12.5

million of long-term debt, non-current portion. Total long-term debt of

$25

million was with affiliates of Deerfield Management, L.P. (Deerfield), who held a security interest in substantially all of our assets (Deerfield Loan).

November 1,

we announced that we had completed a series of transactions to generate short-term cash and potentially enable future capital transactions. Effective

October 27, 2017,

LPH Investments Limited (LPH), a wholly-owned subsidiary of Lee’s Pharmaceutical Holdings Limited (Lee’s) acquired

$10

million of newly issued shares of our common stock, representing a controlling interest in our Company. At the same time, we reached an agreement with Deerfield to restructure and retire the outstanding

$25

million long-term debt, and entered into a nonbinding memorandum of understanding with Battelle (Battelle MOU) outlining potential terms to restructure certain accounts payable related to our device development activities with Battelle. In connection with the Battelle MOU, Battelle executed and delivered a waiver of its rights to receive payments under a liquidation preference pursuant to Series A Convertible Preferred Stock held by Battelle and the related Certificate of Designation of Preferences, Rights and Limitations effective

February 15, 2017 (

the foregoing transactions with LPH, Deerfield and Battelle are collectively referred to in this Quarterly Report on Form

-Q as the

November 2017

Restructuring).

See

, “– Note

– Subsequent Events.”

Although we believe that the

November 2017

Restructuring has improved our financial position

and

better positions us to raise the capital needed to fund on-going operations and development plans, we expect to incur continuing significant losses and will require significant additional capital to further advance our AEROSURF clinical development program, satisfy our current obligations and support our operations for the next several years. Moreover, we do

not

have sufficient existing cash and cash equivalents for at least the next year following the date that these financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern within

one

year after the date that these financial statements are issued.

To potentially alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans to seek additional capital through the following: (i) all or a combination of strategic transactions, and other potential alliances and collaborations focused on markets outside the U.S., as well as potential combinations (including by merger or acquisition) or other corporate transactions; and (ii) through public or private equity offerings. There can be

assurance that these alternatives will be available, or if available, that we will have sufficient cash resources and liquidity to fund our development activities and business operations for at least the next year following the date that these financial statements are issued. Accordingly, management has concluded that substantial doubt exists with respect to our ability to continue as a going concern through

one

year after the issuance of these financial statements.

As of

November 1, 2017,

after closing the

November 2017

Restructuring, we had cash and cash equivalents of

$5.4

million. While we seek the additional capital that we require, we are working with our vendors and service providers

to extend payment terms of certain obligations and our available cash.

We believe that, before any additional financings, we will have sufficient cash resources to partially satisfy our existing obligations and fund our operations into

January 2018.

These

financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do

not

include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Our ability to secure the capital that we will require through equity financings and other similar transactions is subject to regulatory and other constraints, including: (i)

our common stock is currently quoted

on the OTCQB

Market (OTCQB), which is operated by OTC Markets Group Inc., under the symbol WINT and

may

experience periods of illiquidity; (ii)

our common stock is currently considered a “penny stock,” such that brokers are required to adhere to more stringent market rules, which could result in reduced trading activity and trading levels in our common stock and limited or

analyst coverage; (iii) because we are

longer listed on a national securities exchange, we are

not

eligible to file a Form S-

registration statement and our recent Form S-

has expired; (iv) without a Form S-

we are

not

able to use our ATM Program; (v) our controlling stockholder

may

not

approve management proposals to increase the number of shares of common stock authorized under our Amended and Restated Certificate of Incorporation, as amended, which could impair our ability to conduct equity financings or enter into certain strategic transactions (mergers and acquisitions) that require stockholder approval under Delaware law; (vi) our capital structure, which currently consists of common stock, convertible preferred stock, pre-funded warrants and warrants to purchase common stock

may

make it difficult to conduct equity-based financings; and (vii) negative conditions in the broader financial and geopolitical markets. In light of the foregoing, we expect that we will more likely conduct securities offerings as private placements with registration rights, which we would register under a registration statement on Form S-

or other transactions, any of which could result in substantial equity dilution of stockholders’ interests.

In the event that we cannot raise sufficient capital, we

may

be forced to consider transactions on less-than-favorable terms,

or limit or cease our development activities. If we are unable to raise the required capital, we

may

be forced to curtail all of our activities and, ultimately, cease operations. Even if we are able to raise sufficient capital, such financings

may

only be available on unattractive terms, or result in significant dilution of stockholders’ interests and, in such event, the market price of our common stock

may

decline.

We have from time to time collaborated with research organizations and universities to assess the potential utility of our KL

surfactant in studies funded in part through non-dilutive grants issued by U.S. Government-sponsored drug development programs, including grants in support of initiatives related to our AEROSURF clinical development program. In late

May 2017,

we announced that we have been awarded

$0.9

million under a previously announced Phase II Small Business Innovation Research Grant (SBIR) valued at up to

$2.6

million from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to support the AEROSURF phase

clinical trial.

We currently are determining whether, as a subsidiary of Lee

’s, we continue to be eligible for SBIR grants.

We also have received from time to time grants that support medical and biodefense-related initiatives under programs that encourage private sector development of medical countermeasures against chemical, biological, radiological and nuclear terrorism threat agents, and pandemic influenza, and provide a mechanism for federal acquisition of such countermeasures. Although there can be

assurance, we expect to pursue potential additional funding opportunities as they arise and expect that we

may

qualify for similar programs in the future.

As of

September 30, 2017

, and

November 8, 2017,

we had outstanding

0.9

million pre-funded warrants issued in a

July 2015

public offering, of which the entire exercise price was prepaid upon issuance, and

3,203

convertible preferred shares issued in the

February 2017

private placement offering. Each preferred share is convertible into

1,000

shares of common stock. Upon exercise of the pre-funded warrants and conversion of the convertible preferred shares, we would issue common shares to the holders and receive

additional proceeds.

In addition, as of

September 30, 2017,

there were

120

million shares of common stock and

million shares of preferred stock authorized under our Amended and Restated Certificate of Incorporation, as amended, and approximately

85.0

million shares of common stock and approximately

million shares of preferred stock available for issuance and

not

otherwise reserved.

Note 3 - Basis of Presentation

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Basis of Accounting [Text Block]

Note

–

Basis of Presentation

The

se interim unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information in accordance with the instructions to Form

-Q. Accordingly, they do

not

include all of the information and footnotes required by U.S. GAAP for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. Operating results for the

three

and

nine

months ended

September 30, 2017

are

not

necessarily indicative of the results that

may

be expected for the year ending

December

31,

2017.

There have been

changes to our critical accounting policies since

December 31, 2016.

For a discussion of our accounting policies,

see

, “– Note

– Summary of Significant Accounting Policies” in this Quarterly Report on Form

-Q, and “– Note

– Accounting Policies and Recent Accounting Pronouncements” in the Notes to Consolidated Financial Statements in our

2016

Form

-K. Readers are encouraged to review those disclosures in conjunction with this Quarterly Report on Form

-Q.

Note 4 - Stockholders' Equity

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

Note

–

Stockholders

’ Equity

February 2017

Private Placement

February 15, 2017,

we completed a private placement offering of

7,049

Series A Convertible Preferred Stock units

at a price per unit of

$1,495,

for an aggregate purchase price of approximately

$10.5

million, including

$1.6

million of non-cash consideration representing a reduction in amounts due and accrued as of

December 31, 2016

for current development services that otherwise would have become payable in cash in the

first

and

second

quarters of

2017.

Each unit consists of: (i)

one

share of Series A Convertible Preferred Stock, par value

$0.001

per share (Preferred Shares); and (ii)

1,000

Series A-

Warrants (Warrants) to purchase

one

share of common stock at an exercise price equal to

$1.37

per share. Each Preferred Share

may

be converted at the holder's option at any time into

1,000

shares of common stock at a conversion price of

$1.37

per share. The Warrants

may

be exercised beginning

August 15, 2017

and through

February 15, 2024.

The Preferred Shares and the Warrants

may

not

be converted or exercised to the extent that the holder would, following such exercise or conversion, beneficially own more than

9.99%

(or other lesser percent as designated by each holder) of our outstanding shares of common stock. In the event of a liquidation, including without limitation, the sale of substantially all of our assets and certain mergers and other corporate transactions (as defined in the Certificate of Designation of Preferences, Rights and Limitations relating to the Preferred Shares), the holder of Preferred Shares will have a liquidation preference that could result in the holder receiving a return of its initial investment before any payments are made to holders of common stock, and then participating with other equity holders until it has received in the aggregate up to

three

times its original investment.

In addition to the offering, the securities purchase agreement also provides that, until

February 13, 2018,

the investors are entitled to participate in subsequent bona fide capital raising transactions that we

may

conduct.

As of

November

2017,

3,846

Preferred Shares have been converted into

3,846,000

shares of common stock and

3,203

Preferred Shares remain outstanding.

At-the-Market (ATM) Program

During the

nine

months ended

September 30, 2017,

we completed offerings of our common stock under our ATM Program of

847,147

shares. This resulted in an aggregate purchase price of approximately

$1,082,000

(

$1,036,000

net) for the

nine

month period ended

September 30, 2017.

During the

three

and

nine

months ended

September 30, 2016,

we completed offerings of our common stock under our ATM Program of

159,051

shares and

187,022

shares, respectively. This resulted in an aggregate purchase price of approximately

$432,000

(

$402,000

net) and

$503,000

(

$471,000

net), respectively, for the

three

and

nine

month periods ended

September 30, 2016.

Effective

May 5, 2017,

were

longer able to make use of our ATM Program (

see

, “– Note

– Liquidity Risks and Management’s Plans”).

Note 5 - Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Significant Accounting Policies [Text Block]

Note

–

Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements, in conformity with U.S.

GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Severance

Effective

February 1, 2016,

we terminated the Employment Agreement

between ourselves and our then-President and Chief Executive Officer (Former CEO). During the

first

quarter of

2016,

we incurred a severance charge of

$1.2

million in general and administrative expense under the terms of the Former CEO’s employment agreement, including

$0.2

million related to stock option expense for certain options that continued to vest through

August 1, 2017.

Of the

$1.0

million in severance

not

related to stock-based compensation,

$0.9

million was paid as of

September 30, 2017.

During the

second

quarter of

2016,

we incurred a severance charge of

$0.4

million related to a

May 2016

workforce reduction that was a component of a broader effort to initiate cash conservation and other cost reduction measures.

July 13, 2017,

we implemented a reduction in workforce by

employees, representing approximately

42%

of our total workforce, from

employees. The reduction was across all functions of the Company and affected employees were eligible for certain severance and other benefits resulting in a severance charge of

$0.2

million in the

third

quarter of

2017.

Deferred Revenue

Deferre

d revenue represents amounts collected but

not

yet earned and includes

$1.0

million received in

July 2017

for an upfront license fee in connection with the License Agreement with Lee’s. The License Agreement constitutes a multiple-element arrangement and revenue will be recognized as deliverables are completed and all revenue recognition criteria have been met.

Research and Development Expense

We account for research and development expense by the following categories: (a) product development and manufacturing, (b)

medical and regulatory operations, and (c) direct preclinical and clinical programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred.

Net Loss

er Common Share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period.

As of

September 30, 2017

and

2016,

the number of shares of common stock potentially issuable upon the conversion of preferred stock or exercise of stock options and warrants was

18.2

million and

9.4

million shares, respectively. For the

three

and

nine

months ended

September 30, 2017

and

2016,

all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.

In accordance with Accounting Standards Codification Topic

260,

Earnings per Share,

when calculating diluted net loss per common share, a gain associated with the decrease in the fair value of warrants classified as derivative liabilities results in an adjustment to the net loss; and the dilutive impact of the assumed exercise of these warrants results in an adjustment to the weighted average common shares outstanding. We utilize the treasury stock method to calculate the dilutive impact of the assumed exercise of warrants classified as derivative liabilities. For the

three

and

nine

months ended

September 30, 2017

and

2016,

the effect of the adjustments for warrants classified as derivative liabilities was anti-dilutive.

We do

not

have any components of other comprehensive income (loss).

Beneficial Conversion Feature

The issuance of

our Preferred Shares in the

first

quarter of

2017

(

see

, “– Note

– Stockholders’ Equity”) resulted in a beneficial conversion feature, which arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor (or in the money) at inception due to the conversion option having an effective conversion price that is less than the fair value of the underlying stock at the commitment date. We recognized the beneficial conversion feature by allocating the relative fair value of the conversion option, which is the number of shares of common stock available upon conversion multiplied by the difference between the effective conversion price per share and the fair value of common stock per share on the commitment date, to additional paid-in capital, resulting in a discount on the Preferred Shares. As the Preferred Shares are immediately convertible by the holders, the discount allocated to the beneficial conversion feature was immediately accreted and recognized as a

$3.6

million

one

-time, non-cash deemed dividend to the preferred shareholders during the

first

quarter of

2017.

An additional discount to the Preferred Shares

$4.5

million was created due to the allocation of proceeds to the Warrants which were issued with the Preferred Shares. This discount is amortized proportionately as the Preferred Shares are converted. For the

three

and

nine

month periods ended

September 30, 2017,

we recognized a non-cash deemed dividend to the preferred shareholders of

$1.9

million and

$2.4

million, respectively, related to the Preferred Shares converted during the periods.

Rece

Adopted

Accounting

Standards

August 2014,

the

Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU)

2014

15,

Presentation of Financial Statements

–

Going Concern

(Subtopic

205

Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern

, which defines management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. Substantial doubt about an entity's ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within

one

year after the date that the financial statements are issued (or are available to be issued). We adopted ASU

2014

effective

December 31, 2016.

Management has concluded that substantial doubt exists with respect to our ability to continue as a going concern through

one

year after the issuance of these financial statements (s

, “ – Note

– Liquidity Risks and Management's Plans”).

March 2016,

the FASB issued ASU

2016

09,

Compensation - Stock Compensation (Topic

718

): Improvements to Employee Share-Based Payment Accounting

. This update addresses the income tax effects of stock-based payments and eliminates the windfall pool concept, as all of the tax effects related to stock-based payments will now be recorded at settlement (or expiration) through the income statement. The new guidance also permits entities to make an accounting policy election for the impact of forfeitures on the recognition of expense for stock-based payment awards. Forfeitures can be estimated or recognized when they occur. We adopted ASU

2016

during the

three

months ended

March 31, 2017

and will continue to recognize stock compensation expense with estimated forfeitures. The adoption did

not

have a material impact on our unaudited condensed consolidated financial statements and is

not

expected to have an impact on the annual

2017

financial statements.

November 2016,

the FASB issued ASU

2016

18,

Statement of Cash Flows (Topic

230

): Restricted Cash

. The new standard requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. We adopted ASU

2016

March 31, 2017

on a retrospective basis. As a result, beginning-of-period cash, cash equivalents and restricted cash in the statement of cash flows increased by

$0.2

million for each of the

nine

-month periods ended

September 30, 2017

and

2016.

Recent Accounting Pronouncements

May 2014,

the FASB

issued ASU

2014

09,

Revenue from Contracts with Customers (Topic

606

)

, which requires an entity to recognize revenue at an amount that reflects the consideration to which the entity expects to be entitled in exchange for transferring goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the annual period ending

December 31, 2018

and interim periods within that annual period. An entity can elect to apply the guidance under

one

of the following

two

methods: (i) retrospectively to each prior reporting period presented, referred to as the full retrospective method or (ii) retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings, referred to as the modified retrospective method. The Company has

not

yet completed its final review of the impact of this guidance including the new disclosure requirements, as it is continuing to evaluate the impacts of adoption and the implementation approach to be used. The Company plans to adopt the new standard effective

January 1, 2018

using the modified retrospective method. The Company continues to monitor additional changes, modifications, clarifications or interpretations being undertaken by the FASB, which

may

impact its current conclusions.

May 2017,

the FASB issued ASU

2017

09,

Compensation—Stock Compensation (Topic

718

): Scope of Modification Accounting

. This ASU clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The ASU is effective prospectively for the annual period ending

December 31, 2018

and interim periods within that annual period. Early adoption is permitted. We are currently evaluating the effect that ASU

2017

may

have on our consolidated financial statements and related disclosures.

Note 6 - Fair Value of Financial Instruments

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Fair Value Disclosures [Text Block]

Note

–

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on

three

levels of inputs, of which the

first

two

are considered observable and the last unobservable, as follows:

	●	Level 1 – Quoted prices in active markets for identical assets and liabilities.
	●	Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	●	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Fair Value on a Recurring Basis

The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented:

	Fair Value		Fair value measurement using
	September 30,
(in thousands)	2017		Level 1		Level 2		Level 3

Assets:
Cash and cash equivalents	$	1,752	$	1,752	$	-	$	-
Certificate of deposit		225		225		-		-
Total Assets	$	1,977	$	1,977	$	-	$	-

	Fair Value		Fair value measurement using
	December 31,
(in thousands)	2016		Level 1		Level 2		Level 3

Assets:
Cash and cash equivalents	$	5,588	$	5,588	$	-	$	-
Certificate of deposit		225		225		-		-
Total Assets	$	5,813	$	5,813	$	-	$	-

The following table summarizes changes in the fair value of common stock warrant liability

measured on a recurring basis using Level

inputs for the

nine

months ended

September 30, 2016

representing the write-off of the remaining liability upon expiration of the underlying warrants in

February 2016.

Balance at January 1, 2016	$	223
Change in fair value of common stock warrant liability		(223	)
Balance at September 30, 2016	$	-

Fair Value of Long-Term Debt

September 30, 2017,

the estimated fair value of the Deerfield Loan (

see,

“– Note

– Long-term Debt”) was

$23.0

million, compared to a carrying value for current and non-current portions of

$25.0

million. The estimated fair value of the Deerfield Loan is based on discounting the future contractual cash flows to the present value at the valuation date. This analysis utilizes certain Level

unobservable inputs, including current cost of capital. Considerable judgment is required to interpret market data and to develop estimates of fair value. The estimates presented are

not

necessarily indicative of amounts that could be realized in a current market exchange. The use of alternative market assumptions and estimation methodologies could have a material effect on these estimates of fair value. The methodology and assumptions do

not

take into consideration the restructuring and retirement of the Deerfield Loan effective

November 1, 2017 (

see

, “– Note

– Subsequent Events”).

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 7 - Loan Payable

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Short-term Debt [Text Block]

Note

–

Loan Payable

Loan Payable consists solely of amounts due under a loan agreement with

Lee’s (HK).

August 14, 2017,

we entered into a loan agreement (Loan Agreement) with Lee’s (HK). Under the Loan Agreement, Lee’s (HK) agreed to lend us up to

$3.9

million (Loan), to be funded at Lee’s (HK)’s sole discretion in

three

equal installments on

August 15,

September 10

and

October 10, 2017.

The Loan was to be used to support AEROSURF development activities and sustain our operations through

October 31, 2017,

while we and Lee’s (HK) negotiated the SPA and related agreements. The Loan accrued interest at a rate of

12%

per annum. We received the

three

installments of

$1.3

million from Lee's (HK) in accordance with the schedule. As partial consideration for the SPA, the outstanding principal balance of the Loan was applied in full satisfaction of a like amount of cash consideration payable by Lee’s (HK) at the closing of the SPA, and the Loan was discharged in full (

see

, “– Note

– Subsequent Events”).

As of

September 30, 2017,

accrued interest on the Loan was $

28,000.

As partial consideration for the Loan, the Company and Lee

’s (HK) also agreed to amend the License, Development and Commercialization Agreement dated as of

June 12, 2017

between the parties (License Agreement) and have entered into Amendment

No.

to the License Agreement (the Amendment). Under the terms of the Amendment, reductions have been made to certain of the milestone and royalty payments. As a result, the Company

may

receive up to

$35.8

million (previously,

$37.5

million) in potential clinical, regulatory and commercial milestone payments. The options to add Japan to the Licensed Territory (as defined in the License Agreement) and to manufacture the Company’s aerosol delivery device in and for the Licensed Territory are made effective immediately. In addition, Zhaoke Pharmaceutical (Hefei) Co. Ltd. an affiliate of Lee’s (HK), has been made a party to the License Agreement. Except as set forth in the Amendment, all other terms and conditions of the License Agreement remain in full force and effect.

Note 8 - Long-term Debt

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Long-term Debt [Text Block]

Note

–

Long-term Debt

Long-term debt consists solely of amounts due under the Deerfield Loan for the periods presented:

	September 30,		December 31,
(in thousands)	2017		2016

Current portion	$	12,500	$	-
Non-current portion		12,500		25,000
Total Deerfield Loan	$	25,000	$	25,000

The principal amount of the loan is payable in

two

equal annual installments of

$12.5

million, payable in each of

February 2018

and

2019.

See

, “Note

– Subsequent Events”.

The following amounts comprise the Deerfield Loan interest expense for the periods presented:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2017		2016		2017		2016

Amortization of prepaid interest expense	$	276	$	347	$	819	$	1,435
Cash interest expense		260		191		771		191
Total interest expense	$	536	$	538	$	1,590	$	1,626

Amortization of prepaid interest expense represents non-cash amortization of

million of units

purchased by Deerfield in our

July 2015

public offering and accepted in satisfaction of

million of future interest payments calculated at an interest rate of

8.75%

under the Deerfield Loan. Cash interest expense represents interest at an annual rate of

8.25%

on the outstanding principal amount, paid in cash on a quarterly basis.

Note 9 - Stock Options and Stock-based Employee Compensation

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Note

–

Stock Options and Stock-Based Employee Compensation

We recognize in our condensed consolidated financial statements all stock-based awards to employees and non-employee directors based on their fair value on the date of grant, calculated using the Black-Scholes option-pricing model. Compensation expense related to stock-based awards is recognized ratably over the vesting period, which for employees is typically

three

years.

A summary of activity under our long-term incentive plans is presented below:

(in thousands, except for weighted-average data) Stock Options	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (In Yrs)

Outstanding at January 1, 2017		1,142		$	14.66
Granted		822			1.23
Forfeited or expired		(258	)		9.43
Outstanding at September 30, 2017		1,706		$	8.98		8.0

Vested and exercisable at September 30, 2017		612		$	21.55		6.0

Vested and expected to vest at September 30, 2017		1,597		$	9.13		7.9

The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula based on the following weighted average assumptions:

	Nine Months Ended September 30,
	2017			2016

Weighted average expected volatility		79	%		78	%
Weighted average expected term (in years)		6.6			5.7
Weighted average risk-free interest rate		2.22	%		1.4	%
Expected dividends		-			-

The table below summarizes the total stock-based compensation expense included in the statements of operations for the periods presented:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2017		2016		2017		2016

Research and development	$	77	$	140	$	360	$	462
General and administrative		101		133		372		664
Total	$	178	$	273	$	732	$	1,126

Note 10 - Subsequent Events

9 Months Ended

Sep. 30, 2017

Notes to Financial Statements

Subsequent Events [Text Block]

Note

–

Subsequent Events

Effective

October 27, 2017,

we entered into the SPA with LPH Investments Limited (LPH), a company incorporated in the Cayman Islands with limited liability. LPH is a wholly-owned subsidiary of Lee’s. Under the SPA, LPH invested

$10

million (the Investment) in our Company and acquired

46,232,085

shares of our common stock (the Shares), at a price of

$0.2163

per share, which represents a

15%

premium over the average of the daily volume-weighted average price per share (VWAP) over the

-day trading period ending on and including the date of the SPA. Following the transactions described in the SPA, LPH beneficially owned

73%

of our issued and outstanding shares of common stock. The Investment includes cancellation of

$3.9

million in outstanding loans

(

$2.6

million of which was recorded as loan payable as of

September 30, 2017)

that we borrowed from Lee’s (HK) under the Loan Agreement, effective

August 14, 2017,

between ourselves and Lee's (HK). Pursuant to the SPA, we granted LPH the right to appoint up to

two

individuals to serve on our Board of Directors, and LPH

may

designate such individuals on or prior to the

30th

day following the closing of the transactions contemplated by the SPA (the Closing). In addition, the SPA also amends the executive employment agreement of each of our President and Chief Executive Officer (Craig Fraser), Senior Vice President and Chief Financial Officer (John A. Tattory) and Senior Vice President and Chief Medical Officer (Steven G. Simonson, M.D.), such that in lieu of the Annual Bonuses (as defined in each executive's employment agreement) that would have been payable to the executives during the

-month period following the Closing, the executives are entitled to an award of equity under our

2011

Long-Term Incentive Plan, as amended, having a value when issued equal to the combined total value of the

2017

and

2018

Target Bonus Amounts (as defined in each executive's employment agreement) and vesting in

two

equal installments on

March 15, 2018

and

March 15, 2019.

Under the terms of the SPA, we also granted to LPH a preemptive right to purchase in future offerings of equity securities up to that number of shares of the Company's equity securities needed to maintain LPH's percentage of beneficial ownership of the Company's outstanding voting stock immediately prior to each such offering, subject to certain limitations and exclusions.

Contemporaneously with the execution of the SPA,

we and LPH entered into a registration rights agreement pursuant to which we agreed to provide certain registration rights with respect to the Shares under the SPA, which rights are limited to registration of up to

25%

of the Shares during the initial

-month period following the closing of the SPA. We issued the Shares to LPH pursuant to Rule

506

(b) of Regulation D and Regulation S under, and Section

(a)(

) of, the Securities Act of

1933.

Contemporaneously with the execution of the SPA,

we and Deerfield entered into an Exchange and Termination Agreement (the Exchange and Termination Agreement). Under the Exchange and Termination Agreement, (i) promissory notes evidencing an aggregate principal amount of

$25

million that we owed to Deerfield under a Facility Agreement dated as of

February 13, 2013 (

Facility Agreement), as amended from time to time, and (ii) warrants to purchase up to

500,000

shares of our common stock at an exercise price of

$39.34

per share held by Deerfield (the Deerfield Warrants) were cancelled in consideration for (i) a cash payment in the aggregate amount of

$2.5

million, (ii) an aggregate of

1,422,250

shares of common stock and (iii) the right to receive certain milestone payments (Milestone Payments) based on achievement of specified development and commercial milestones related to the Company's AEROSURF

development program, which, if achieved, could potentially total up to

$15

million.

Contemporaneously with the execution of the Exchange and Termination Agreement,

we and Deerfield entered into a registration rights agreement pursuant to which we agreed to provide certain registration rights with respect to the shares of common stock issued to Deerfield under the Exchange and Termination Agreement. We issued the shares of common stock to Deerfield pursuant to Rule

506

(b) of Regulation D under, and Section

(a)(

) of, the Securities Act of

1933.

November 1, 2017 (

the Closing Date),

we, Lee's and Deerfield consummated the transactions contemplated by the SPA and the Exchange and Termination Agreement. Effective upon the Closing Date, (i) the Facility Agreement, including the outstanding promissory notes thereunder, and (ii) that certain Security Agreement, dated as of

February 13, 2013,

among Deerfield and us were cancelled and terminated.

To facilitate consummation of the SPA, effective upon the Closing, Battelle, holder of an aggregate of

1,095

shares of Series A Convertible Preferred Stock, par value

$0.001

per share, of the Company (Preferred Shares), executed a waiver wherein Battelle waived its right to the Liquid

ity Preference (as defined in the Designation of Preferences, Rights and Limitations for the Preferred Shares) with respect to their Preferred Shares. In addition, we and Battelle entered into a non-binding memorandum of understanding outlining the key terms for a potential restructuring of the amounts due to Battelle under development and collaboration agreements between ourselves and Battelle.

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2017
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Severance Cost [Policy Text Block]	Severance Effective February 1, 2016, we terminated the Employment Agreement between ourselves and our then-President and Chief Executive Officer (Former CEO). During the first quarter of 2016, we incurred a severance charge of $1.2 million in general and administrative expense under the terms of the Former CEO’s employment agreement, including $0.2 million related to stock option expense for certain options that continued to vest through August 1, 2017. Of the $1.0 million in severance not related to stock-based compensation, $0.9 million was paid as of September 30, 2017. During the second quarter of 2016, we incurred a severance charge of $0.4 million related to a May 2016 workforce reduction that was a component of a broader effort to initiate cash conservation and other cost reduction measures. On July 13, 2017, we implemented a reduction in workforce by 20 employees, representing approximately 42% of our total workforce, from 48 to 28 employees. The reduction was across all functions of the Company and affected employees were eligible for certain severance and other benefits resulting in a severance charge of $0.2 million in the third quarter of 2017.
Revenue Recognition, Deferred Revenue [Policy Text Block]	Deferred Revenue Deferre d revenue represents amounts collected but not yet earned and includes $1.0 million received in July 2017 for an upfront license fee in connection with the License Agreement with Lee’s. The License Agreement constitutes a multiple-element arrangement and revenue will be recognized as deliverables are completed and all revenue recognition criteria have been met.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense We account for research and development expense by the following categories: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred.
Earnings Per Share, Policy [Policy Text Block]	Net Loss p er Common Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. As of September 30, 2017 and 2016, the number of shares of common stock potentially issuable upon the conversion of preferred stock or exercise of stock options and warrants was 18.2 million and 9.4 million shares, respectively. For the three and nine months ended September 30, 2017 and 2016, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share. In accordance with Accounting Standards Codification Topic 260, Earnings per Share, when calculating diluted net loss per common share, a gain associated with the decrease in the fair value of warrants classified as derivative liabilities results in an adjustment to the net loss; and the dilutive impact of the assumed exercise of these warrants results in an adjustment to the weighted average common shares outstanding. We utilize the treasury stock method to calculate the dilutive impact of the assumed exercise of warrants classified as derivative liabilities. For the three and nine months ended September 30, 2017 and 2016, the effect of the adjustments for warrants classified as derivative liabilities was anti-dilutive. We do not have any components of other comprehensive income (loss).
Stockholders' Equity Note, Convertible Preferred Stock, Beneficial Conversion Feature, Policy [Policy Text Block]	Beneficial Conversion Feature The issuance of our Preferred Shares in the first quarter of 2017 ( see , “– Note 4 – Stockholders’ Equity”) resulted in a beneficial conversion feature, which arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor (or in the money) at inception due to the conversion option having an effective conversion price that is less than the fair value of the underlying stock at the commitment date. We recognized the beneficial conversion feature by allocating the relative fair value of the conversion option, which is the number of shares of common stock available upon conversion multiplied by the difference between the effective conversion price per share and the fair value of common stock per share on the commitment date, to additional paid-in capital, resulting in a discount on the Preferred Shares. As the Preferred Shares are immediately convertible by the holders, the discount allocated to the beneficial conversion feature was immediately accreted and recognized as a $3.6 million one -time, non-cash deemed dividend to the preferred shareholders during the first quarter of 2017. An additional discount to the Preferred Shares of $4.5 million was created due to the allocation of proceeds to the Warrants which were issued with the Preferred Shares. This discount is amortized proportionately as the Preferred Shares are converted. For the three and nine month periods ended September 30, 2017, we recognized a non-cash deemed dividend to the preferred shareholders of $1.9 million and $2.4 million, respectively, related to the Preferred Shares converted during the periods.
New Accounting Pronouncements, Policy [Policy Text Block]	Rece nt ly Adopted Accounting Standards In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014 - 15, Presentation of Financial Statements – Going Concern (Subtopic 205 - 40 ): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern , which defines management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. Substantial doubt about an entity's ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or are available to be issued). We adopted ASU 2014 - 15 effective December 31, 2016. Management has concluded that substantial doubt exists with respect to our ability to continue as a going concern through one year after the issuance of these financial statements (s ee , “ – Note 2 – Liquidity Risks and Management's Plans”). In March 2016, the FASB issued ASU 2016 - 09, Compensation - Stock Compensation (Topic 718 ): Improvements to Employee Share-Based Payment Accounting . This update addresses the income tax effects of stock-based payments and eliminates the windfall pool concept, as all of the tax effects related to stock-based payments will now be recorded at settlement (or expiration) through the income statement. The new guidance also permits entities to make an accounting policy election for the impact of forfeitures on the recognition of expense for stock-based payment awards. Forfeitures can be estimated or recognized when they occur. We adopted ASU 2016 - 09 during the three months ended March 31, 2017 and will continue to recognize stock compensation expense with estimated forfeitures. The adoption did not have a material impact on our unaudited condensed consolidated financial statements and is not expected to have an impact on the annual 2017 financial statements. In November 2016, the FASB issued ASU 2016 - 18, Statement of Cash Flows (Topic 230 ): Restricted Cash . The new standard requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. We adopted ASU 2016 - 18 on March 31, 2017 on a retrospective basis. As a result, beginning-of-period cash, cash equivalents and restricted cash in the statement of cash flows increased by $0.2 million for each of the nine -month periods ended September 30, 2017 and 2016. Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014 - 09, Revenue from Contracts with Customers (Topic 606 ) , which requires an entity to recognize revenue at an amount that reflects the consideration to which the entity expects to be entitled in exchange for transferring goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the annual period ending December 31, 2018 and interim periods within that annual period. An entity can elect to apply the guidance under one of the following two methods: (i) retrospectively to each prior reporting period presented, referred to as the full retrospective method or (ii) retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings, referred to as the modified retrospective method. The Company has not yet completed its final review of the impact of this guidance including the new disclosure requirements, as it is continuing to evaluate the impacts of adoption and the implementation approach to be used. The Company plans to adopt the new standard effective January 1, 2018 using the modified retrospective method. The Company continues to monitor additional changes, modifications, clarifications or interpretations being undertaken by the FASB, which may impact its current conclusions. In May 2017, the FASB issued ASU 2017 - 09, Compensation—Stock Compensation (Topic 718 ): Scope of Modification Accounting . This ASU clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The ASU is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. We are currently evaluating the effect that ASU 2017 - 09 may have on our consolidated financial statements and related disclosures.

Note 6 - Fair Value of Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2017

Notes Tables

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Fair Value		Fair value measurement using
	September 30,
(in thousands)	2017		Level 1		Level 2		Level 3

Assets:
Cash and cash equivalents	$	1,752	$	1,752	$	-	$	-
Certificate of deposit		225		225		-		-
Total Assets	$	1,977	$	1,977	$	-	$	-

	Fair Value		Fair value measurement using
	December 31,
(in thousands)	2016		Level 1		Level 2		Level 3

Assets:
Cash and cash equivalents	$	5,588	$	5,588	$	-	$	-
Certificate of deposit		225		225		-		-
Total Assets	$	5,813	$	5,813	$	-	$	-

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Balance at January 1, 2016	$	223
Change in fair value of common stock warrant liability		(223	)
Balance at September 30, 2016	$	-

Note 8 - Long-term Debt (Tables)

9 Months Ended

Sep. 30, 2017

Notes Tables

Schedule of Long-term Debt Instruments [Table Text Block]

	September 30,		December 31,
(in thousands)	2017		2016

Current portion	$	12,500	$	-
Non-current portion		12,500		25,000
Total Deerfield Loan	$	25,000	$	25,000

Schedule of Debt Instrument Interest Expense [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2017		2016		2017		2016

Amortization of prepaid interest expense	$	276	$	347	$	819	$	1,435
Cash interest expense		260		191		771		191
Total interest expense	$	536	$	538	$	1,590	$	1,626

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

Note 9 - Stock Options and Stock-based Employee Compensation (Tables)

9 Months Ended

Sep. 30, 2017

Notes Tables

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

(in thousands, except for weighted-average data) Stock Options	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (In Yrs)

Outstanding at January 1, 2017		1,142		$	14.66
Granted		822			1.23
Forfeited or expired		(258	)		9.43
Outstanding at September 30, 2017		1,706		$	8.98		8.0

Vested and exercisable at September 30, 2017		612		$	21.55		6.0

Vested and expected to vest at September 30, 2017		1,597		$	9.13		7.9

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Nine Months Ended September 30,
	2017			2016

Weighted average expected volatility		79	%		78	%
Weighted average expected term (in years)		6.6			5.7
Weighted average risk-free interest rate		2.22	%		1.4	%
Expected dividends		-			-

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2017		2016		2017		2016

Research and development	$	77	$	140	$	360	$	462
General and administrative		101		133		372		664
Total	$	178	$	273	$	732	$	1,126

Note 2 - Liquidity Risks and Management's Plans (Details Textual) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 27, 2017 USD ($)	May 31, 2017 USD ($)	Sep. 30, 2017 USD ($) shares	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) shares	Sep. 30, 2016 USD ($)	Nov. 08, 2017 shares	Nov. 01, 2017 USD ($)	Dec. 31, 2016 USD ($) shares
Cash and Cash Equivalents, at Carrying Value			$ 1,752		$ 1,752				$ 5,588
Accounts Payable and Accrued Liabilities, Current			29,500		29,500
Long-term Debt, Current Maturities			12,500		12,500
Long-term Debt, Excluding Current Maturities			12,500		12,500				$ 25,000
Revenue from Grants			$ 17	$ 961	$ 1,383	$ 1,142
Preferred Stock, Shares Outstanding \| shares			3,203		3,203				0
Common Stock, Shares Authorized \| shares			120,000,000		120,000,000				60,000,000
Preferred Stock, Shares Authorized \| shares			5,000,000		5,000,000				5,000,000
Common Stock Capital Shares Available for Issuance \| shares			85,000,000		85,000,000
Preferred Stock Capital Shares Available for Issuance \| shares			5,000,000		5,000,000
Prefunded Warrants [Member] \| July 2015 Public Offering [Member]
Class of Warrant or Right, Outstanding \| shares			900,000		900,000
Series A Units [Member] \| Private Placement [Member]
Preferred Stock, Shares Outstanding \| shares			3,203		3,203
Series A Warrant [Member] \| Private Placement [Member]
Preferred Stock Units, Number of Warrants					1,000
Phase II Small Business Innovation Research Grant from the NHLBI [Member]
Revenue from Grants		$ 900
Grant Award		$ 2,600
Subsequent Event [Member]
Cash and Cash Equivalents, at Carrying Value								$ 5,400
Preferred Stock, Shares Outstanding \| shares							3,203
Subsequent Event [Member] \| Prefunded Warrants [Member] \| July 2015 Public Offering [Member]
Class of Warrant or Right, Outstanding \| shares							900,000
Subsequent Event [Member] \| Series A Units [Member] \| Private Placement [Member]
Preferred Stock, Shares Outstanding \| shares							3,203
Lee's [Member] \| Subsequent Event [Member]
Share Purchase, Consideration Transferred to The Company to Acquire Controlling Interest	$ 10,000
Deerfield Loan [Member]
Long-term Debt, Current Maturities			$ 12,500		$ 12,500
Long-term Debt, Excluding Current Maturities			12,500		12,500				25,000
Long-term Debt			$ 25,000		$ 25,000				$ 25,000
Deerfield Loan [Member] \| Subsequent Event [Member]
Extinguishment of Debt, Amount	$ 25,000

Note 4 - Stockholders' Equity (Details Textual) - USD ($)			3 Months Ended	9 Months Ended
	Nov. 08, 2017	Feb. 15, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Preferred Stock, Par or Stated Value Per Share		$ 0.001		$ 0.001		$ 0.001
Preferred Stock, Shares Outstanding				3,203		0
Proceeds from Issuance of Common Stock				$ 1,036,000	$ 471,000
Subsequent Event [Member]
Preferred Stock, Shares Outstanding	3,203
Conversion of Series A Convertible Preferred Stock into Common Stock [Member] \| Subsequent Event [Member]
Conversion of Stock, Shares Converted	3,846
Conversion of Stock, Shares Issued	3,846,000
Private Placement [Member]
Convertible Preferred Stock Units, Price Per Unit		$ 1,495
Private Placement [Member] \| Series A Units [Member]
Stock Issued During Period, Shares, New Issues		7,049
Gross Proceeds From Issuance Of Units		$ 10,500,000
Non-cash Consideration Received		$ 1,600,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Preferred Stock, Shares Outstanding				3,203
Private Placement [Member] \| Series A Units [Member] \| Subsequent Event [Member]
Preferred Stock, Shares Outstanding	3,203
Private Placement [Member] \| Series A Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.37
Class of Warrants, May Not Exercise To Extent, Percentage		9.99%
Stifel ATM Program [Member]
Stock Issued During Period, Shares, New Issues			159,051	847,147	187,022
Stock Issued During Period, Value, New Issues			$ 432,000	$ 1,082,000	$ 503,000
Proceeds from Issuance of Common Stock			$ 402,000	$ 1,036,000	$ 471,000

Note 5 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands, shares in Millions			1 Months Ended	3 Months Ended				9 Months Ended
	Jul. 13, 2017	Feb. 01, 2016 USD ($)	Jul. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) shares	Sep. 30, 2016 USD ($) shares	Jun. 30, 2017
Severance Costs				$ 200
Restructuring and Related Cost, Number of Positions Eliminated	20
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent	42.00%
Entity Number of Employees	28									48
Number of Shares of Common Stock Potentially Issuable upon the Exercise of Stock Options and Warrants \| shares								18.2	9.4
Preferred Stock Dividends, Income Statement Impact				1,915	$ 3,600			$ 6,051
Preferred Stock, Discount on Shares				4,500				4,500
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect								(3,836)	$ (26,339)
Accounting Standards Update 2016-18 [Member]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect					200
Reclassification of Cash and Cash Equivalents to Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Member] \| Quarter Ended March 31, 2016 [Member]
Prior Period Reclassification Adjustment					$ 200
Conversion of Preferred Stock [Member]
Preferred Stock Dividends, Income Statement Impact				$ 1,900				2,400
License Agreement With Lee’s [Member]
Deferred Revenue, Additions			$ 1,000
The 2016 Restructuring Plan [Member]
Severance Costs							$ 400
Former CEO's Employment Agreement [Member]
Payments for Restructuring								$ 900
Former CEO's Employment Agreement [Member] \| Stock Option Expense [Member]
Severance Costs		$ 200
Former CEO's Employment Agreement [Member] \| Not Related to Stock-based Compensation [Member]
Severance Costs		1,000
Selling, General and Administrative Expenses [Member] \| Former CEO's Employment Agreement [Member]
Severance Costs		$ 1,200

Note 6 - Fair Value of Financial Instruments (Details Textual) - Deerfield Loan [Member] $ in Millions	Sep. 30, 2017 USD ($)
Estimate of Fair Value Measurement [Member]
Long-term Debt, Fair Value	$ 23
Reported Value Measurement [Member]
Long-term Debt, Fair Value	$ 25

Note 6 - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Assets:
Cash and cash equivalents	$ 1,752	$ 5,588
Total Assets	1,977	5,813
Certificates of Deposit [Member]
Assets:
Certificate of deposit	225	225
Fair Value, Inputs, Level 1 [Member]
Assets:
Cash and cash equivalents	1,752	5,588
Total Assets	1,977	5,813
Fair Value, Inputs, Level 1 [Member] \| Certificates of Deposit [Member]
Assets:
Certificate of deposit	225	225
Fair Value, Inputs, Level 2 [Member]
Assets:
Cash and cash equivalents
Total Assets
Fair Value, Inputs, Level 2 [Member] \| Certificates of Deposit [Member]
Assets:
Certificate of deposit
Fair Value, Inputs, Level 3 [Member]
Assets:
Cash and cash equivalents
Total Assets
Fair Value, Inputs, Level 3 [Member] \| Certificates of Deposit [Member]
Assets:
Certificate of deposit

Note 6 - Fair Value of Financial Instruments - Level 3 Rollforward (Details) - Fair Value, Inputs, Level 3 [Member] - Derivative Financial Instruments, Liabilities [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Balance	$ 223
Change in fair value of common stock warrant liability	(223)
Balance

Note 7 - Loan Payable (Details Textual) - USD ($)						9 Months Ended
Note 7 - Loan Payable (Details Textual) - USD ($)	Oct. 10, 2017	Sep. 10, 2017	Aug. 15, 2017	Aug. 14, 2017	Jun. 12, 2017	Sep. 30, 2017	Sep. 30, 2016
Proceeds from Short-term Debt						$ 2,600,000
License Agreement With Lee’s [Member]
License Agreement, Contingent Receivable, Maximum				$ 35,800,000	$ 37,500,000
Lee's [Member]
Debt Instrument, Face Amount				$ 3,900,000
Debt Instrument, Interest Rate, Stated Percentage				12.00%
Proceeds from Short-term Debt		$ 1,300,000	$ 1,300,000
Interest Payable, Current						$ 28,000
Lee's [Member] \| Subsequent Event [Member]
Proceeds from Short-term Debt	$ 1,300,000

Note 8 - Long-term Debt (Details Textual) - Deerfield Loan [Member] $ in Millions	9 Months Ended
	Sep. 30, 2017 USD ($)
Debt Instrument Repayment of Principal Portion Number of Installments	2
Long-term Debt, Maturities, Repayments of Principal in Year Two	$ 12.5
Debt Instrument, Periodic Payment, Principal	5.0
Debt Instrument, Periodic Payment, Interest	$ 5.0
Debt Instrument, Interest Rate, Stated Percentage	8.75%
Debt Instrument, Interest Rate During Period	8.25%
Long-term Debt, Maturities, Repayments of Principal in Year Three	$ 12.5

Note 8 - Long-term Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Long-term debt, current portion	$ 12,500
Long-term debt, non-current portion	12,500	25,000
Deerfield Loan [Member]
Long-term debt, current portion	12,500
Long-term debt, non-current portion	12,500	25,000
Total Deerfield Loan	$ 25,000	$ 25,000

Note 8 - Long-term Debt - Long-term Debt Interest Expense (Details) - Deerfield Loan [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Amortization of prepaid interest expense	$ 276	$ 347	$ 819	$ 1,435
Cash interest expense	260	191	771	191
Total interest expense	$ 536	$ 538	$ 1,590	$ 1,626

Note 9 - Stock Options and Stock-based Employee Compensation (Details Textual)	9 Months Ended
	Sep. 30, 2017
2011 Long-term Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period	3 years

Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Stock Option Activity (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2017 $ / shares shares
Shares Outstanding, Beginning Balance (in shares) \| shares	1,142
Weighted Average Exercise Price, Outstanding, at Beginning Period (in dollars per share) \| $ / shares	$ 14.66
Shares Granted (in shares) \| shares	822
Weighted Average Exercise Price, Granted (in dollars per share) \| $ / shares	$ 1.23
Shares Forfeited or Expired (in shares) \| shares	(258)
Weighted Average Exercise Price, Forfeited or Expired (in dollars per share) \| $ / shares	$ 9.43
Shares Outstanding, Ending Balance (in shares) \| shares	1,706
Weighted Average Exercise Price, Outstanding, at Ending Period (in dollars per share) \| $ / shares	$ 8.98
Weighted Average Remaining Contractual Life, Outstanding (Year)	8 years
Shares Vested and Exercisable (in shares) \| shares	612
Weighted Average Exercise Price, Vested and Exercisable (in dollars per share) \| $ / shares	$ 21.55
Weighted Average Remaining Contractual Life, Vested and Exercisable (Year)	6 years
Vested and expected to vest (in shares) \| shares	1,597
Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share) \| $ / shares	$ 9.13
Weighted Average Remaining Contractual Life, Vested and Expected to Vest (Year)	7 years 328 days

Note 9 - Stock Options and Stock-based Employee Compensation - Stock Options Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Weighted average expected volatility	79.00%	78.00%
Weighted average expected term (in years) (Year)	6 years 219 days	5 years 255 days
Weighted average risk-free interest rate	2.22%	1.40%
Expected dividends

Note 9 - Stock Options and Stock-based Employee Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock-based compensation expense	$ 178	$ 273	$ 732	$ 1,126
Research and Development Expense [Member]
Stock-based compensation expense	77	140	360	462
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 101	$ 133	$ 372	$ 664

Note 10 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Oct. 27, 2017	Sep. 30, 2017	Feb. 15, 2017	Dec. 31, 2016
Preferred Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001	$ 0.001
Exchange and Termination Agreement [Member] \| Deerfield Management, L.P. [Member] \| Deerfield Loan Warrants [Member]
Class of Warrant or Right, Number of Warrants Cancelled	500,000
Class of Warrant or Right, Exercise Price of Cancelled Warrants	$ 39.34
Deerfield Loan [Member] \| Exchange and Termination Agreement [Member] \| Deerfield Management, L.P. [Member]
Extinguishment of Debt, Amount	$ 25.0
Repayments of Long-term Debt	$ 2.5
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations	1,422,250
Milestone Payments Potentially Due in the Future for the Extinguishment of Debt and Warrants	$ 15.0
Subsequent Event [Member] \| Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001
Subsequent Event [Member] \| Battelle [Member] \| Series A Preferred Stock [Member]
Preferred Stock, Convertible, Shares, Liquidity Preference Waived	1,095
Subsequent Event [Member] \| Deerfield Loan [Member]
Extinguishment of Debt, Amount	$ 25.0
Subsequent Event [Member] \| LPH [Member] \| Acquisition of Windtree [Member]
Business Combination, Consideration Transferred	$ 10.0
Business Acquisition, Shares Acquired, Number	46,232,085
Business Acquisition, Share Price	$ 0.2163
Business Acquisition, Shares Acquired, Price Per Share, Percentage Premium	15.00%
Business Acquisition, Percentage of Voting Interests Acquired	73.00%
Business Combination, Consideration Transferred, Liabilities Cancelled	$ 3.9
Business Combination, Consideration Transferred, Loans Payable Cancelled	$ 2.6
Business Combination, Number of Individuals Acquirer May Appoint to the Acquiree's Board of Directors	2
Business Combination, Registration Rights Agreement, Maximum Rights Percentage in First 18 Months	25.00%